Literature DB >> 16449969

Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression.

P La1, A Desmond, Z Hou, A C Silva, R W Schnepp, X Hua.   

Abstract

Menin is encoded by the tumor suppressor gene MEN1 that is mutated in patients with an inherited tumor syndrome, multiple endocrine neoplasia type 1 (MEN1). Although menin is a nuclear protein and directly binds to DNA through its nuclear localization signals (NLSs), the precise role for each of the NLSs in nuclear translocation and gene expression remains to be elucidated. Here, we show that point mutations in three individual NLSs, NLS1, NLS2, and a novel accessory NLS, NLSa, do not block nuclear translocation, but compromise the ability of menin to repress expression of the endogenous insulin-like growth factor binding protein-2 (IGFBP-2) gene. This repression is not released by an inhibitor of histone deacetylases. Although subtle mutations in menin NLSs do not affect menin association with chromatin, they abolish menin binding to the IGFBP-2 promoter in vivo. Furthermore, each of the NLSs is also crucial for menin-mediated induction of caspase 8 expression. Together, these results suggest that menin may act as a scaffold protein in coordinating activation and repression of gene transcription and that its NLSs play a more important role in controlling gene transcription than merely targeting menin into the nucleus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449969     DOI: 10.1038/sj.onc.1209400

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  The Rhox genes.

Authors:  James A MacLean; Miles F Wilkinson
Journal:  Reproduction       Date:  2010-04-29       Impact factor: 3.906

2.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

5.  The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization.

Authors:  Yan Wang; Atsushi Ozawa; Shadia Zaman; Nijaguna B Prasad; Settara C Chandrasekharappa; Sunita K Agarwal; Stephen J Marx
Journal:  Cancer Res       Date:  2010-12-02       Impact factor: 12.701

Review 6.  Epigenetic regulation by the menin pathway.

Authors:  Zijie Feng; Jian Ma; Xianxin Hua
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

7.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

Review 8.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 9.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

10.  SUMO modification of menin.

Authors:  Zi-Jie Feng; Buddha Gurung; Guang-Hui Jin; Xiao-Lu Yang; Xian-Xin Hua
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.